Bank of New York Mellon
KYMR icon

Bank of New York Mellon’s Kymera Therapeutics KYMR Stock Holding History

Bank of New York Mellon’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.7M Buy
215,588
+22,388
+12% +$1.92M ﹤0.01% 1496
2026
Q1 		$16.1M Buy
193,200
+452
+0.2% +$35.8K ﹤0.01% 1662
2025
Q4 		$15M Buy
192,748
+40,296
+26% +$2.72M ﹤0.01% 1695
2025
Q3 		$8.63M Buy
152,452
+21,738
+17% +$980K ﹤0.01% 2016
2025
Q2 		$5.7M Buy
130,714
+3,837
+3% +$132K ﹤0.01% 2196
2025
Q1 		$3.47M Sell
126,877
-216
-0.2% -$7.87K ﹤0.01% 2414
2024
Q4 		$5.11M Buy
127,093
+5,448
+4% +$246K ﹤0.01% 2280
2024
Q3 		$5.76M Sell
121,645
-34,566
-22% -$1.53M ﹤0.01% 2226
2024
Q2 		$4.66M Buy
156,211
+25,317
+19% +$877K ﹤0.01% 2375
2024
Q1 		$5.26M Sell
130,894
-2,697
-2% -$96.5K ﹤0.01% 2302
2023
Q4 		$3.4M Buy
133,591
+7,327
+6% +$131K ﹤0.01% 2567
2023
Q3 		$1.76M Buy
126,264
+208
+0.2% +$4.18K ﹤0.01% 2884
2023
Q2 		$2.9M Sell
126,056
-839,911
-87% -$24.1M ﹤0.01% 2629
2023
Q1 		$28.6M Sell
965,967
-23,999
-2% -$774K 0.01% 1356
2022
Q4 		$24.7M Sell
989,966
-35,278
-3% -$941K 0.01% 1420
2022
Q3 		$22.3M Buy
1,025,244
+582
+0.1% +$15.3K 0.01% 1440
2022
Q2 		$20.2M Buy
1,024,662
+338,468
+49% +$7.91M ﹤0.01% 1529
2022
Q1 		$29M Buy
686,194
+155,476
+29% +$6.57M 0.01% 1436
2021
Q4 		$33.7M Buy
530,718
+29,838
+6% +$1.74M 0.01% 1400
2021
Q3 		$29.4M Buy
500,880
+432,300
+630% +$25.1M 0.01% 1490
2021
Q2 		$3.33M Buy
68,580
+30,244
+79% +$1.31M ﹤0.01% 2687
2021
Q1 		$1.49M Sell
38,336
-1,924
-5% -$116K ﹤0.01% 3097
2020
Q4 		$2.5M Buy
+40,260
New +$1.96M ﹤0.01% 2711

Other funds holding KYMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon's KYMR Position: Q2 2026 in Review

Bank of New York Mellon increased its Kymera Therapeutics (KYMR) stake by 12% in Q2 2026, buying an estimated $1.92M and bringing the position to 215,588 shares worth $24.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1496.

Bank of New York Mellon first reported a position in KYMR in Q4 2020 and has held it in 23 quarters since. The position peaked at $33.7M in Q4 2021. 141 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Bank of New York Mellon held 215,588 shares of Kymera Therapeutics worth $24.7M as of Q2 2026.
  • Bank of New York Mellon bought 22,388 Kymera Therapeutics shares in Q2 2026, an estimated $1.92M.
  • Kymera Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1496 holding.
  • Bank of New York Mellon first reported a position in Kymera Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Bank of New York Mellon's Kymera Therapeutics position peaked at $33.7M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.